ENTITY
CureVac NV

CureVac NV (CVAC US)

14
Analysis
Health Care • United States
CureVac N.V. operates as a global clinical-stage biopharmaceutical company. The Company focuses on developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people. CureVac serves customers worldwide.
more
bullish•Moderna
•20 Jan 2022 23:30

Is It Time For Moderna To Boost Share Buyback And Start Paying Dividends?

Our analysis suggests that Moderna may boost share buyback and announce dividend payments in 2022 as cash pile will exceed $20 billion

Share
bullish•CureVac NV
•23 Nov 2020 03:03

CureVac Stock May Surge Another 20-30% Under New Bull-Case Scenario

We see further upside potential for CureVac shares as the probability of success is increasing for its vaccine candidate CVnCoV and key mRNA-based...

Share
bullish•CureVac NV
•13 Nov 2020 08:28

Success of Moderna’s COVID-19 Vaccine May Give a Boost to Stocks of Messenger RNA Companies

mRNA-based COVID-19 vaccine producers made a big step forward to defeat coronavirus and prevent future pandemics around the world

Share
bullish•CureVac NV
•28 Sep 2020 04:21

Expecting First Results From Phase 1 Clinical Trials Of COVID-19 Vaccine In October

CureVac shares have been under selling pressure and fell ~20% in September. For the same period shares of key rivals Moderna and BioNTech rose 7%...

Share
bullish•CureVac NV
•21 Aug 2020 03:05

CureVac May Supply ~225M of Potential COVID-19 Vaccine Doses. A Big Win Over Moderna and BioNTech

Today German coronavirus vaccine developer CureVac has concluded an Advanced Purchase Agreement (APA) to provide all EU Member States with up to...

Share
x